Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 7Polycystic Ovary Syndrome 2Neoplasms 2Urinary Bladder Neoplasms 1Stage I Prostate Adenocarcinoma 1Prostatic Neoplasms 1Osteoporosis 1Infertility 1Esophageal Neoplasms 1Endometrial Neoplasms 1Diarrhea 1Cardiovascular Diseases 1Carcinoma, Squamous Cell 1Brain Neoplasms 1Anovulation 1Adenocarcinoma 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Raloxifene Hydrochloride × Clear all
NCT00710970 2022-01-24

Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment

Baylor College of Medicine

Phase 2 Completed
28 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡